Nanog Activators
Nanog Activators encompass a diverse group of chemical compounds that can enhance the expression or activity of the Nanog protein. This assortment of compounds does not belong to a single unified chemical class, but represents a broad spectrum of compounds connected through their shared ability to stimulate Nanog. Often, these activators function by influencing cellular signaling pathways that regulate Nanog expression. For instance, a subset of these activators target the TGF-beta signaling pathway, a vital regulator of cellular differentiation. Compounds like SB431542, a selective inhibitor of TGF-beta receptor kinases, inhibit this pathway, thereby fostering a cellular environment that encourages Nanog expression.
Moreover, Nanog Activators include compounds that inhibit the MEK/ERK pathway, like PD0325901. This pathway has roles in various cellular processes, including differentiation, and its inhibition can sustain elevated levels of Nanog expression. Activators can also be compounds that stimulate the Wnt signaling pathway, known for promoting pluripotency. BIO and CHIR99021, both inhibitors of GSK-3, a crucial negative regulator of the Wnt pathway, exemplify this category. Nanog Activators further extend to histone deacetylase (HDAC) inhibitors such as sodium butyrate and valproic acid. By promoting a more open chromatin structure, these compounds facilitate the transcription of genes like Nanog. Finally, certain Nanog Activators operate through less-defined mechanisms, like parthenolide, but have been observed to increase Nanog expression under specific conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
CHIR99021 is a selective inhibitor of glycogen synthase kinase-3 (GSK-3), indirectly activating Nanog. By inhibiting GSK-3, CHIR99021 prevents the phosphorylation and degradation of Nanog, leading to its stabilization and increased activity. This indirect activation of Nanog influences stem cell pluripotency and self-renewal pathways. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
BIO is a potent and selective GSK-3 inhibitor that indirectly activates Nanog. By inhibiting GSK-3, BIO prevents the degradation of Nanog, leading to its stabilization and increased activity. This indirect activation of Nanog influences cellular processes associated with stem cell pluripotency and self-renewal. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01 is a selective inhibitor of the transforming growth factor-beta (TGF-β) type I receptor, ALK5, indirectly activating Nanog. By blocking TGF-β signaling, A83-01 disrupts the negative regulation on Nanog expression, leading to increased Nanog levels. This indirect activation contributes to the maintenance of stem cell pluripotency and self-renewal capabilities. | ||||||
Thiazovivin | 1226056-71-8 | sc-361380 sc-361380A | 10 mg 25 mg | $284.00 $634.00 | 15 | |
Thiazovivin is a selective inhibitor of Rho-associated protein kinase (ROCK), indirectly activating Nanog. By inhibiting ROCK, Thiazovivin influences the cytoskeletal dynamics and signaling pathways that regulate Nanog expression, leading to increased Nanog levels. This indirect activation contributes to the maintenance of stem cell pluripotency and self-renewal capabilities. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV939 is an inhibitor of tankyrase, indirectly activating Nanog. By inhibiting tankyrase, XAV939 stabilizes Axin, leading to the inhibition of GSK-3 and preventing the degradation of Nanog. This indirect activation influences stem cell pluripotency and self-renewal pathways, contributing to the maintenance of Nanog activity. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108 is a DNA methyltransferase (DNMT) inhibitor that indirectly activates Nanog. By inhibiting DNMT, RG108 prevents the methylation of Nanog promoter regions, leading to increased Nanog expression. This indirect activation influences the epigenetic regulation of Nanog and contributes to the maintenance of stem cell pluripotency and self-renewal capabilities. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Shown to increase Nanog expression in glioma cells, possibly by suppressing NF-kB signaling. | ||||||